TrialCompass TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT06534060

MB-105 in Patients With CD5 Positive T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is testing Genetic: MB-105 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 12 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Genetic: MB-105 (BIOLOGICAL): MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.

Drugs / treatments
Genetic: MB-105
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

MB-105 in Patients With CD5 Positive T-cell Lymphoma

NCT06534060

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is testing Genetic: MB-105 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 12 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • May require specific number of prior treatments

What's being tested

Genetic: MB-105 (BIOLOGICAL): MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.

Drugs / treatments: Genetic: MB-105

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 46 patients

Primary endpoint: Adverse events (AEs) per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; Objective response rate (ORR)

Ages: 18 Years to —

Start date: 2025-02-15 | Est. completion: 2029-12

Locations

12 US sites · 12 total

California, Colorado, Florida, Iowa, Massachusetts, Nebraska, New York, North Carolina, Ohio, Oregon, Texas

Contact

Federica Giordano, Ph.D. | clinicaltrials@march.bio | 7138980838

Sponsor: March Biosciences Inc (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06534060

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.